NCT00809419 - A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Age Related Macular Degeneration

Interventions

DEVICE

NeoVista Ophthalmic System

A single procedure with the NeoVista Ophthalmic System, with Lucentis (0.5mg) administered on an as needed basis for three years.

Trial Locations (5)

Retinal Institute of Hawaii, Honolulu

Retina Consultants of Arizona, Phoenix

Rabin Medical Center, Petah Tikva

Tel-Aviv Medical Center, Tel Aviv

Kings College Hospital, London